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ABSTRACT
It is estimated that 19% of adolescents in Poland begin their sexual life when they are 15 years old and more than 50% of 
people aged 17–19 years have already had their first sexual contact. World Health Organization recommends teenagers to 
use the method of ‘dual protection’ (condom and other method of contraception, i.e. intrauterine devices).
In this study, we sought to present our own experience in the field of the use of levonorgestrel-releasing intrauterine devices 
in adolescents and to compare it with the experience of other researchers worldwide.
Low- dose levonorgestrel-releasing intrauterine device is safe and effective method of contraception in adolescents. It is 
also an alternative treatment used in heavy chronic abnormal uterine bleeding. It can be also used as an alternative in 
women with cyanotic heart disease who have contraindications for standard contraception.
Gynecologists and pediatricians should be well informed in the topic of intrauterine device use among adolescents and 
they should provide them reliable knowledge in this field.
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INTRODUCTION
Adolescent sexual behavior
It is estimated that 19% of adolescents in Poland be-
gin their sexual life when they are 15 years old and more 
than 50% of people aged 17–19 years have already had their 
first sexual contact [1]. World Health Organization (WHO) 
estimates that 16 million adolescent girls get pregnant 
each year [2]. Although the access to medical information 
is getting easier, health-care worldwide is better than in 
the past and there is general technological progress, the 
number of teenage pregnancies is still growing. Unwanted 
pregnancy is connected with many consequences such as 
medical consequences of early pregnancy, sexually transmit-
ted infections (STIs), unsafe abortions, social and personal 
consequences. Because of that, adolescent pregnancy pre-
vention is one of the most important health-care issues of 
the twenty-first century.
European Society of Contraception and Reproductive 
Health Care emphasized that only 55% of young Europeans 
have access to education in the field of sexuality. Studies 
show that teenagers often don’t know about the methods 
of contraception and risk sexual behaviors [3]. 
World Health Organization recommends teenagers to 
use the method of ‘dual protection’ (condom and other 
method of contraception) in order to simultaneously pro-
tect against pregnancy and STIs. Intrauterine devices (IUD) 
represent long-acting reversible contraception (LARC) and 
they are safe, effective and well-tolerated method of con-
traception for adolescents. 
The Polish Society of Gynecologists and Obstetricians 
remains consistent with the recommendations of WHO. They 
emphasize that the method of contraception should be safe, 
effective, reversible, easy in use and easily accessible [4]. 
In this study, we sought to present our own experience 
in the field of the use of levonorgestrel-releasing intrauterine 
devices (LNG-IUDs) in adolescents and to compare it with 
the experience of other researchers worldwide.
CURRENT STATE OF KNOWLEDGE AND OWN 
EXPERIENCE
Levonorgestrel-releasing intrauterine devices in 
adolescents
Over 150 million women worldwide use the IUDs for 
contraception [5]. As a result of various contraceptive ac-
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tions, the efficacy rate of the LNG-IUD is high, which makes 
it a great option for young women. 
Four hormonal levonorgestrel-releasing IUDs (LNG-IUDs) 
are currently available in Poland (containing different doses 
of LNG: 13.5 mg, 19.5 mg, 52 mg). IUDs should not be used in 
patients before the first menstruation. We should emphasize 
that only some devices are dedicated for teenagers [data 
about being used in women under 18 years old is contained 
in the Summary of Product Characteristics (SmPC)]. What 
is more, the devices have different dimensions. We recom-
mend using low-dose IUDs that are fitted to a smaller uterus. 
Six — step procedure to introduce IUD
Physicians from INTRA (Intrauterine Contraception 
Translating Research Into Action) have proposed 7-min-
utes algorithm of introducing intrauterine device, which 
we highly recommend in everyday practice [6]: 
Step 1
•	 Adjust patient’s expectations to her needs. Evaluate 
experience and knowledge about various contracep-
tive methods. 
•	 Ask simple questions: What contraceptive did you use? 
Are you currently sexually active? Are you planning 
a pregnancy?
Step 2 
•	 Present long-acting reversible contraception (LARC). 
•	 Regardless of the reason for the visit, ask the patient 
about her contraception.
•	 Assess the patient’s knowledge and interest in intrau-
terine contraception.
Step 3
•	 Inform about the potential benefits of intrauterine con-
traception.
•	 When the patient is interested, expand your information 
to include: high efficacy, no need for daily, weekly or 
monthly administration, rapid reversibility, cost- effec-
tiveness, and quick insertion in most women.
Step 4
•	 Confirm method reliability and dispel doubts. 
•	 Inform about potential side effects such as the risk 
of ectopic pregnancy, perforation, expulsion or pro-
lapse, infection, and changes in menstrual bleeding 
patterns. 
•	 Refer to side effects for other methods of contraception 
and pregnancy itself.
Step 5
•	 Help to make a decision. 
•	 Share your knowledge and clinical experience. Ask if 
the patient is interested in seeing the system. Be honest 
when you talk about discomfort issues.
Step 6 
•	 Confirm the decision and plan the insertion of the IUD. 
•	 Inform that if serious side effects occur, they should 
contact their physician immediately.
In addition, The Polish Society of Gynecologists and 
Obstetricians recommends performing before introducing 
a new method of contraception:
•	 Physical examination including blood pressure measure;
•	 Gynaecological examinations;
•	 Transvaginal ultrasound examinations;
•	 Breast examinations;
•	 Cytology test.
According to WHO recommendations, hormonal con-
traception can be introduced in teenagers [2]: 
•	 2 years after menarche;
•	 In the case of dysmenorrhea.
LNG-IUDs are also a great alternative for women with 
cyanotic heart disease with contraindication to standard 
hormonal therapy use.
LNG-IUD as a method of treatment of abnormal 
uterine bleeding 
Abnormal uterine bleeding (AUB) is one of the most 
frequent condition with which teenagers present in gyneco-
logic office. The most common causes of AUB in adolescents 
are anovulation and coagulopathy. The initial management 
of AUB in adolescents is based on whether the AUB is acute 
or chronic. The second type occurs when uterine bleeding 
is abnormal in volume, regularity, and/or timing and has 
occurred for most of the past 6 months. It does not require 
urgent treatment (unlike acute AUB). LNG-IUD is an excel-
lent management option for a patient experiencing chronic 
abnormal uterine bleeding. It is more effective than oral 
medication as a treatment for heavy menstrual bleeding and 
it is associated with a greater reduction in heavy menstrual 
bleeding and improvement in quality of life, and appears 
to be more acceptable long term [7]. 
In our practice, we have been using several LNG-IUD as 
an alternative method of treatment in heavy chronic AUB 
in adolescents (off-label treatment) without observing side 
effects. Our experience in this field involves 3 girls aged 
14–16 with contraindications to use estrogens (implementa-
tion of heart valve in childhood, congenital cyanotic heart 
disease). All three patients have not begun their sexual life 
yet. Formal consent from their parents for implementation 
of LNG-IUD was required in all 3 cases. 
We would like to present closer a case of 14-year-old 
girl with cyanotic heart disease who presented with abun-
dant menstruations and irregular cycles. The girl under-
went several cardiac surgeries and she is still prepared 
for subsequent interventions. She uses permanent an-
ticoagulants — under INR control and she has absolute 
contraindications for estrogen use. On physical examina-
tion: peripheral cyanosis, „rod-like fingers”. Gynecological 
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condition was suitable for age (Th3/P3/A3). Gynecological 
transabdominal ultrasound examination revealed an image 
suitable for age, without signs of pathology, endometrium 
of 5 mm. Hemoglobin level on first visit was 8 g%. The 
patient was diagnosed with severe AUB. Firstly, we tried 
using dydrogesterone for several months with no effect. 
Final therapeutic decision was made at the age of 15: we 
have inserted intrauterine hormonal contraceptive systems 
(LNG-releasing) under general anesthesia, after obtaining 
full formal parental consent. Patient’s clinical state was 
re-evaluated after 1, 3 and 6 months. We have observed 
complete blockage of uterine bleeding with no side effects. 
Our second patient was a 15 years old girl with Turner 
Syndrome (45 X0/46 XX), after 3 years of GH therapy with 
spontaneous menarche at the age of 11. In addition, she 
suffered from congenital heart disease (bipolar aortic valve 
— mild form, under clinical follow-up) and she had relative 
contraindications for estrogen use. The patient presented 
with very abundant menstruation, lasting up to 21 days and 
irregular menstrual cycles. Her gynecological condition was 
suitable for age (Th5/P5/A5). Gynecological transabdominal 
ultrasound examination revealed an image suitable for 
age, without signs of pathology, endometrium of 8mm. 
Hemoglobin level on first visit was 10 g%. The patient was 
diagnosed with moderate AUB. First stage therapy consisted 
of dydrogesterone 10mg twice a day between 16–25th cycle’s 
days (insufficient effect). Our final therapeutic decision was 
inserting intrauterine hormonal contraceptive systems (LNG-
releasing) at the age of 16.5 under general anesthesia, after 
obtaining full formal parental consent. Patient’s clinical state 
was re-evaluated after 1, 3 and 6 months. We have observed 
complete blockage of uterine bleeding with no side effects. 
LNG-IUD in the treatment of endometriosis and 
chronic pelvic pain
Although LNG-IUD is not dedicated to be used as 
a first-line treatment of endometriosis and chronic pelvic 
pain (no registration in SmPC), we have experience in treat-
ing young patients with diagnosed endometriosis (off-label 
treatment). In 6 adolescents we have introduced low-dose 
LNG-IUD with success. Firstly, the girls were treated with 
standard methods, unfortunately without any effect. All six 
patients have not begun their sexual life yet. Formal con-
sent from their parents for implementation of LNG-IUD was 
required in all 6 cases. Literature lack information about the 
use of LNG-IUD in adolescents suffering from endometriosis, 
so we should conduct further research in this topic. 
Effects on the menstrual bleeding are expected in most 
women using the LNG-IUDs. Such changes are the result of 
a direct effect of levonorgestrel on the endometrium and 
may not be correlated with ovarian activity. Irregular bleed-
ing and spotting often occur in the first months of use. Then, 
as a result of strong endometrial inhibition, the duration and 
reduction of menstrual bleeding are reduced. Minor bleed-
ing often turns into rare bleeding or amenorrhea. In clinical 
trials, rare bleeding and/or amenorrhea developed gradu-
ally. In non-menstrual women, multiple pregnancy tests are 
not necessary unless there are other signs of pregnancy. 
If the bleeding gets worse and/or becomes more irregular 
over time, appropriate diagnostic measures should be taken 
because irregular bleeding may be a sign of endometrial 
polyps, hyperplasia or cancer. Heavy bleeding may be also 
a symptom of expulsion of the intrauterine therapeutic sys-
tem. In most women, after the IUD is put on, the menstrual 
bleeding pattern changes. Over time, the percentage of 
women with amenorrhoea and with rare bleeding increases, 
while the percentage of women with prolonged, irregular 
and frequent bleeding decreases [8]. 
Safety 
Some physicians are concerned about using IUDs in 
young women because they are higher risk of STIs. How-
ever, despite concerns, studies show that insertion of IUD 
in young women (including teenagers) is not connected 
with higher risk of STI when compared to older women. 
The risk of pelvic inflammatory disease (PID) in the first 
20 days after insertion is less than 1%, and then decreases 
to around 1 in 1000 [8]. However, the American Pediatric 
Society recommends screening for Chlamydia and Neisseria 
before inserting IUD due to the significant risk of transmis-
sion of infections in the adolescent group [9]. We recom-
mend conducting a precise interview (i.e. information about 
many sexual partners, questions about risk factors of PID, 
the occurrence of PID in the past) with the patient before 
introducing the system [8]. In our practice, we have never 
observed PID in a teenage patient after inserting LNG-IUD. 
CONCLUSIONS
IUDs are considered to be safe and well tolerated 
method of contraception among adolescents. However, 
young women often have to face some barriers connected 
with IUD access (i.e. financial barriers). Gynecologists and 
pediatricians should be well informed in the topic of IUD use 
among adolescents and they should provide them reliable 
knowledge in this field. Teenagers often seek effective, safe 
and easy method of contraception, which does not require 
daily reminding. LNG-IUD should be always considered as 
a method of contraception in young women. 
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